Novartis AG said Monday that a trial to evaluate prostate-cancer drug Pluvicto met its primary endpoint in patients with a specific type of metastatic cancer.
The Swiss drug company
NOVN,
NVS,
said the primary endpoint was to improve progression-free survival, or the time in which patients can live without the disease advancing.
The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.
Write to Cecilia Butini at cecilia.butini@wsj.com
